Synergen Technologies
Investors Count
1Funding, Valuation & Revenue
1 Fundings
Synergen Technologies's latest funding round was a Incubator/Accelerator for on .
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
Incubator/Accelerator |
Date | |
|---|---|
Round | Incubator/Accelerator |
Amount | |
Investors | |
Valuation | |
Revenue | |
Sources |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Synergen Technologies Investors
1 Investors
Synergen Technologies has 1 investors. Chicago Technology Park invested in Synergen Technologies's Incubator/Accelerator funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
1 Incubator/Accelerator | Incubator/Accelerator | Illinois |
First funding | |
|---|---|
Last Funding | |
Investor | |
Rounds | 1 Incubator/Accelerator |
Board Seats | |
Type | Incubator/Accelerator |
Location | Illinois |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Synergen Technologies to Competitors
Progression Therapeutics is a biotechnology company focused on the treatment of primary and metastatic cancer. The Company currently has multiple products in various stages of evaluation, including a tumor suppressor gene product that has demonstrated potent anti-tumor activity both in vitro and in vivo.
Opal Therapeutics is an immunotherapy company focused on therapies for human immunodeficiency virus (HIV) and Hepatitis C (HCV), based on technology from the University of Melbourne.
NovaDigm Therapeutics is developing vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. The company's lead product candidate, NDV-3, is a recombinant glycoprotein vaccine containing a candidal surface antigen, agglutinin-like sequence 3 protein or Als3. Results from a Phase 1 clinical trial demonstrated that a single dose of the NDV-3 vaccine was safe, well-tolerated and induced strong antibody and T-cell immune responses in healthy adults.
PDC Biotech is developing a compound, PDC31 which is being developed for the treatment of preterm labor and primary dysmenorrhea. PDC31 is a peptide antagonist of the prostaglandin F2a (FP) receptor, the lead in a series of FP antagonists exclusively licensed to PDC Biotech GmbH from Theratechnologies, (TSX: TH), a Canadian biopharmaceutical company.
Intercept Pharmaceuticals engages in the development and commercialization of novel therapeutics in the healthcare sector. Its offerings include the development and delivery of medicines for conditions such as primary biliary cholangitis and severe alcohol-associated hepatitis. The company primarily serves the healthcare industry, with a particular emphasis on liver health. It was founded in 2002 and is based in Morristown, New Jersey.
Cosmo is a fully-integrated speciality pharmaceutical company that aims to become engaged in the market of optimised therapies for selected gastro-intestinal diseases. The company's clinical development pipeline specifically addresses treatments for Inflammatory Bowel Diseases (IBD), such as Ulcerative Colitis and Crohn's Disease, as well as for colon infections.
Loading...